353 related articles for article (PubMed ID: 27614621)
1. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
Nozawa M; Inagaki T; Nagao K; Nishioka T; Komura T; Esa A; Kitagawa M; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uejima S; Matsuyama H; Hara I; Uemura H
Int J Clin Oncol; 2014 Aug; 19(4):693-701. PubMed ID: 23912936
[TBL] [Abstract][Full Text] [Related]
4. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
[TBL] [Abstract][Full Text] [Related]
5. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
7. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
10. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
[TBL] [Abstract][Full Text] [Related]
11. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
[TBL] [Abstract][Full Text] [Related]
12. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
13. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
Kashiwabara T; Suda S
BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278
[TBL] [Abstract][Full Text] [Related]
15. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
16. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
Uemura H; Yanagisawa M; Ikeda I; Fujinami K; Iwasaki A; Noguchi S; Noguchi K; Kubota Y;
Int J Clin Oncol; 2013 Jun; 18(3):472-7. PubMed ID: 22491982
[TBL] [Abstract][Full Text] [Related]
17. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
Okegawa T; Higaki M; Matsumoto T; Kase H; Murata A; Noda K; Noda H; Asaoka H; Oshi M; Tomoishi J; Uchida H; Higashihara E; Nutahara K;
Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
[TBL] [Abstract][Full Text] [Related]
20. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
